Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Theratechnologies Inc. - Common Shares (NQ: THTX )

1.520 -0.020 (-1.30%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Theratechnologies Inc. - Common Shares

< Previous 1 2 3 4 5 6 Next >
A Preview Of Theratechnologies's Earnings
Theratechnologies (NASDAQ:THTX) is set to give its latest quarterly earnings report on Thursday, 2022-07-14. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Thursday's session saw 49 companies set new 52-week lows. 
Via Benzinga
The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal 
Via Benzinga
Theratechnologies Earnings Preview
Theratechnologies (NASDAQ:THTX) is set to give its latest quarterly earnings report on Wednesday, 2022-04-13. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More
Biotech stocks managed to carve out modest gains for the week ending April 8, defying the broader market weakness. The defensive nature of the stocks make them appealing in times of risk aversion. 
Via Benzinga
Theratechnologies Q1 2022 Earnings Conference Call On April 13, 2022 At 08:30 AM ET
  Theratechnologies (NASDAQ:THTX) will host a conference call at 08:30 AM ET on April 13, 2022, to discuss Q1 2022 earnings results. 
Via Benzinga
Theratechnologies Q3 Earnings Lags Consensus As Trogarzo Sales Decline
Theratechnologies Inc (NASDAQ: THTX) reported Q3 sales of $17.85 million, +27% Y/Y propelled by higher Egrifta sales of $11.22 million, +64%. The revenue missed... 
Via Benzinga
The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Revance Clarifies Gabellar Line Treatment Review On Track Responding to the... 
Via Benzinga
Exposures Product Safety
Earnings Scheduled For October 13, 2021
Companies Reporting Before The Bell • BlackRock (NYSE:BLK) is estimated to report quarterly earnings at $9.23 per share on revenue of $4.81 billion. • Delta Air... 
Via Benzinga
The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage
Biotech stocks retreated in the week ending Oct. 8, extending losses for the third straight week. Some of the selling in the space was due to money moving out of defensive... 
Via Benzinga
Exposures Product Safety
The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs And More
Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks. Positive tidings from Merck & Co... 
Via Benzinga
Exposures Product Safety
Theratechnologies' IV Push Form Of HIV Treatment At Par With IV Infusion
Theratechnologies Inc (NASDAQ: THTX) has announced results from a study evaluating an intravenous (IV) push form of Trogarzo (ibalizumab-uiyk) for HIV-1 infection... 
Via Benzinga
10 Biggest Price Target Changes For Thursday
Canaccord Genuity cut Theratechnologies Inc. (NASDAQ: THTX) price target from $8 to $3. Theratechnologies shares gained 4.5% to close at $3.71 on Wednesday. Guggenheim lifted... 
Via Benzinga
Theratechnologies In Search Of Potential Partner For Late-Stage NASH Study Of Tesamorelin, Reports Q2 Earnings
Theratechnologies Inc (NASDAQ: THTX) has completed discussions with the FDA and European Medicines Agency regarding its proposed trial design and protocol for its... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 14) Alexion Pharmaceuticals,... 
Via Benzinga
Topics Product Recall
Exposures Legal Product Safety
Earnings Scheduled For July 15, 2021
Companies Reporting Before The Bell • Truist Financial (NYSE:TFC) is estimated to report quarterly earnings at $1.17 per share on revenue of $5.47 billion. •... 
Via Benzinga
Theratechnologies Peptide-Drug Conjugate Shows Better Anti-Metastatic Activity Compared With Docetaxel Alone
Theratechnologies Inc (NASDAQ: THTX) has announced new preclinical in vivo findings on its peptide-drug conjugate (PDC), TH1902. The results demonstrate that... 
Via Benzinga
The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight
Contrary to the strength in the broader market, biotech stocks ended the week ending April 9 lower. The weakness partly reflected a preference for risky bets at the expense of... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 13) Bio-Techne Corporation (... 
Via Benzinga
Exposures Product Safety
Stocks That Hit 52-Week Highs On Tuesday
This morning 106 companies set new 52-week highs. Interesting Highlights: Microsoft (NASDAQ:MSFT) was the largest company by market cap to set a new 52-week high... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.